Recent Quotes

Adamis Pharmaceuticals Corp is a specialty biopharmaceutical company focused on developing and commercializing products in various therapeutic areas, including allergy, opioid overdose, respiratory and inflammatory disease. Its products and product candidates in the allergy, respiratory, and opioid overdose markets include SYMJEPI (epinephrine) Injection 0.3mg and Injection 0.15mg for use in the emergency treatment of acute allergic reactions, including anaphylaxis; a naloxone injection product candidate, ZIMHI, based on the approved Symject injection device and intended for the treatment of opioid overdose; Tempol, an investigational drug; and a Beclomethasone metered dose inhaler product candidate (APC-1000) intended for the treatment of asthma.

Earnings

Q1 2021		Est.		Actual		Surprise
EPS		-0.060		(EXPECTED) 2021-06-25
REV		3.470M		(EXPECTED) 2021-06-25

Q4 2020		Est.		Actual		Surprise
EPS				-0.240
REV		5.710M		3.637M		-2.073M

Analyst Ratings

Date	Analyst Firm	Analyst Name	Action	Rating	Action Price	Prior Price	Target

Related Companies

Ticker	Company	Price	Change	Chg %		Mkt Cap
ADMP	Adamis Pharmaceuticals	1.00	-0.02	-1.96%		148.9M

Adamis Pharmaceuticals Frequently Asked Questions

How do I buy Adamis Pharmaceuticals (ADMP) stock?

You can purchase shares of Adamis Pharmaceuticals (NASDAQ: ADMP) through any online brokerage.

View our list of the best stock brokerages.

Who are Adamis Pharmaceuticals's (ADMP) competitors?

Other companies in Adamis Pharmaceuticals’s space includes: Graybug Vision (NASDAQ:GRAY), Cocrystal Pharma (NASDAQ:COCP), Onconova Therapeutics (NASDAQ:ONTX), Satsuma Pharmaceuticals (NASDAQ:STSA) and SCYNEXIS (NASDAQ:SCYX).

What is the target price for Adamis Pharmaceuticals (ADMP) stock?

The latest price target for Adamis Pharmaceuticals (NASDAQ: ADMP) was reported by Maxim Group on May 13, 2020. The analyst firm set a price target for 1.50 expecting ADMP to rise to within 12 months (a possible 50.00% upside). 0 analyst firms have reported ratings in the last year.

Current Stock Price for Adamis Pharmaceuticals (ADMP)?

The stock price for Adamis Pharmaceuticals (NASDAQ: ADMP) is $1 last updated Fri Jun 11 2021 20:00:03 GMT+0000 (Coordinated Universal Time).

Does Adamis Pharmaceuticals (ADMP) pay a dividend?

There are no upcoming dividends for Adamis Pharmaceuticals.

When is Adamis Pharmaceuticals (NASDAQ:ADMP) reporting earnings?

Adamis Pharmaceuticals’s Q2 earnings are confirmed for after-market on August 16, 2021.

Is Adamis Pharmaceuticals (ADMP) going to split?

There is no upcoming split for Adamis Pharmaceuticals.

What sector and industry does Adamis Pharmaceuticals (ADMP) operate in?

Adamis Pharmaceuticals is in the Consumer Discretionary sector and Multiline Retail industry. They are listed on the NASDAQ.